chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Post vaccine: 6 hours- very sore arm, migraine headache 12 hours- extreme fatigue, drowsiness, muscle aches, headache, blurry vision 12-72 hours-  unable to function due to extreme drowsiness, fatigue (unable to care for child and operate a vehicle) 3 days to 10 days- continue to experience weakness, difficultly lifting things I would otherwise be able to, foggy brain, unable to recall certain words, difficulty staying awake and doing my job
It started with my hands aching and then I had a lot of body aches. By noon, I had a terrible headache and was running a fever. Later, the lymph node under my arm on the side of the injection was swollen and a little painful.
This spontaneous report as received from a nurse practitioner refers to a unspecified number of patients of unknown age and gender. Medical history and concurrent conditions were not reported. On an unknown date the patients were vaccinated with ROTATEQ, 2 ml, oral. No co-suspect and concomitant therapies were reported. On an unknown date the patients were administered doses of ROTATEQ after 32 weeks of age. No adverse events were reported. Additional information has been requested.
Information has been received from a consumer, and from a physician's staff member, concerning a 6 month old white male infant who on 14-DEC-2007 was vaccinated with a dose of pneumococcal 23v polysaccharide vaccine. The physician told the consumer her son was scheduled to receive pneumococcal 4 6B 9V 14 19C 19F 23F conj vaccine (CRM197) (PREVNAR), but pneumococcal 23v polysaccharide vaccine was actually administered. The staff member confirmed there were no adverse reactions noted. No further information is available.
Child has chicken pox reported by school nurse. 3 children in kindergarten out who show immunization to Varivax. Report filled out per request.
Pt states the day after he received the vaccine, pt teeth hurt and he was having lung pain. Pt also stopped smoking the day he received the vaccine. Pt is unsure if symptoms are related to incident. Pt lung pain has resolved.  Pt states that 2 days after he received the vaccine, he complains of hand nerve pain, with his middle and ring finger. The nerve pain is still present. Pt also complains about after getting the vaccine, days later that patient complains of foot/nerve pain. Pt was shot with a bullet in past and had nerve pain before in similar spot and it has returned after receiving the vaccine. Bullet fragments are still in patient.
PT c/o nausea and chills 5 minutes s/p injection.  EMS onsite aware, PT initial VS BP 89/57, HR 85, Resp 20, 99% SaO2, Glucose 94 - PT stated nausea and chills resolved a few minutes later - EMS rechecked BP @ 1420 while sitting - 98/58, and while standing - 101/57 - PT states symptoms have resolved - has a history of feeling lightheaded after giving blood.  PT declined further evaluation/intervention - EMS obtained signed release and PT left facility at approx 1430 in no apparent distress.
tender hardness on the injection site the size of a silver dollar; tender hardness on the injection site the size of a silver dollar; freezing to death;feels very cold; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (tender hardness on the injection site the size of a silver dollar), VACCINATION SITE MASS (tender hardness on the injection site the size of a silver dollar) and FEELING COLD (freezing to death;feels very cold) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Jan-2021, the patient experienced VACCINATION SITE PAIN (tender hardness on the injection site the size of a silver dollar), VACCINATION SITE MASS (tender hardness on the injection site the size of a silver dollar) and FEELING COLD (freezing to death;feels very cold). At the time of the report, VACCINATION SITE PAIN (tender hardness on the injection site the size of a silver dollar), VACCINATION SITE MASS (tender hardness on the injection site the size of a silver dollar) and FEELING COLD (freezing to death;feels very cold) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment and concomitant medications were not provided by reporter.
Patient stated the left side of her face felt numb like she had received a novacaine shot. Assessed for signs of stroke and had no signs. Had her sit for 10 more minutes and she said her face was starting to feel better before she left.
RECEIVED FIRST DOSE MODERNA  LOT# 041L20A ON 1/25/2021 RECEIVED SECOND DOSE PFIZER ON 2/19/2021  LOT # UNKNOWN AT TIME OF THIS REPORT
No adverse event; administered dose of Moderna Primary vaccine that was expired; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administered dose of Moderna Primary vaccine that was expired) and NO ADVERSE EVENT (No adverse event) in a 45-year-old male patient who received mRNA-1273 (Spikevax) (batch nos. 055A22A and 055A22A) for COVID-19 prophylaxis.     Patient did not received any other vaccines in the four weeks prior to COVID-19 vaccine.  The patient's past medical history included Sepsis and Anxiety. Concurrent medical conditions included Drug allergy (Allergic to hydroxyzine) and Seizures.   On 25-Jan-2023, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 27-Feb-2023, received second dose of mRNA-1273 (Spikevax) (Intramuscular) dosage was changed to 1 dosage form. On 27-Feb-2023,  after starting mRNA-1273 (Spikevax), the patient experienced EXPIRED PRODUCT ADMINISTERED (administered dose of Moderna Primary vaccine that was expired). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (administered dose of Moderna Primary vaccine that was expired) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (administered dose of Moderna Primary vaccine that was expired).    No concomitant information was reported. No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-714215 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 07-Mar-2023: Live follow information contains no new information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-714215:Same reporter
Pt states she received pneumovax at pharmacy 2 days ago in afternoon, states upon waking next morning she felt pain in joints and swelling. No edema at office visit today.
Patient was admitted on 01/29/2022 for Acute respiratory failure and hypoxia and pneumonia due to COVID-19. This is considered a breakthrough case
Ongoing diarrhea and abdominal pain which started a week after receiving the 2ed dose of Moderna.
Began having Gelastic (hysterical laughter) seizures within the 3 weeks after his 4 month DTAP and HEPB.
This case was reported by a pharmacist via call center representative and described the occurrence of injection site erythema in a adult patient who received SHINGRIX for prophylaxis. On 18th July 2018, the patient received SHINGRIX. On 18th July 2018, less than a day after receiving SHINGRIX, the patient experienced injection site erythema and injection site pain. On an unknown date, the outcome of the injection site erythema and injection site pain were not recovered/not resolved. It was unknown if the reporter considered the injection site erythema and injection site pain to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The healthcare professional reported that the patient had pain and a red spot at the injection site after vaccination with SHINGRIX. No other details were given. The healthcare professional did not provide patient or vaccine information.
pt recvd vax;sl rash below inject site shortly p/ vax;no acute distress as SOB observed;dph  given; instructed to go ER if SOB devel;
Patient has swelling, redness, and pain on the right thigh.  Came in to the office today to be seen.  Parents gave patient some oral Benadryl and topical hydrocortisone on the  area.
First issue is that the pharmacy gave his doses two weeks apart, not three. As a physician and his daughter I called them to see how this could have happened. They seemed unconcerned. About three weeks later he went into atrial fibrillation rhythm requiring cardioversion. No prior history of arrhythmias.
rash in the back; Redness; itching; lower back,; arm soreness; This spontaneous case was reported by a physician and describes the occurrence of PAIN IN EXTREMITY (arm soreness), RASH (rash in the back), ERYTHEMA (Redness), PRURITUS (itching) and RASH (lower back,) in an 84-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20A) for COVID-19 vaccination.     Concurrent medical conditions included Pulmonary fibrosis, Acid reflux (oesophageal), Hypertension and Cholesterol. Concomitant products included TAMSULOSIN, PREDNISONE, PANTOPRAZOLE, MAGNESIUM, LEVOTHYROXINE and ATORVASTATIN for an unknown indication.    On 20-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Feb-2021, the patient experienced PAIN IN EXTREMITY (arm soreness). On 05-Mar-2021, the patient experienced RASH (rash in the back), ERYTHEMA (Redness), PRURITUS (itching) and RASH (lower back,). On 21-Feb-2021, PAIN IN EXTREMITY (arm soreness) had resolved. At the time of the report, RASH (rash in the back), ERYTHEMA (Redness), PRURITUS (itching) and RASH (lower back,) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
blurry vision- right eye; BRVO; A localized clot (thrombus) development in a branch retinal vein.; This is a spontaneous report from a contactable consumer (patient). This 67-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL9266) on 12Feb2021 02:15 PM in left arm at single dose for COVID-19 immunisation. Medical history included slight asthma, known allergies: sulfa, penicillin. No COVID prior vaccination. Concomitant medications included Vitamins (over-the-counter, other medications in two weeks). No other vaccine in four weeks. The patient previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL9262) on 22Jan2021 03:30 PM in left arm at single dose for COVID-19 immunisation at the age of 67-year-old. The patient was not pregnant, was not pregnant at time of vaccination. No COVID tested post vaccination. On 15Feb2021, within a few days of receiving second dose of vaccine, the patient developed blurry vision of right eye. After seeing a retina specialist, patient was diagnosed with BRVO (retinal vein branch occlusion). The cause of BRVO is a localized clot (thrombus) development in a branch retinal vein. The events resulted in disability or permanent damage. The patient received treatment as anti-VEGF drug - Avastin for the events. Outcome of the events was not recovered.
advice to wait 90 days before receiving the second dose; came down with covid-19; This spontaneous case was reported by a health care professional and describes the occurrence of COVID-19 (came down with covid-19) in a 76-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Knee pain (knee hurts after jogging). Concomitant products included ASPIRIN [ACETYLSALICYLIC ACID] for Knee pain, VITAMINS NOS for an unknown indication.    On 21-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 26-Feb-2021, the patient experienced COVID-19 (came down with covid-19). On 04-Mar-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (advice to wait 90 days before receiving the second dose). On 04-Mar-2021, PRODUCT DOSE OMISSION ISSUE (advice to wait 90 days before receiving the second dose) had resolved. At the time of the report, COVID-19 (came down with covid-19) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   On 04MAR2021 the patient had taken monoclonal antibodies to treat COVID-19 infection and was told to wait 90 days before receiving the second planned dose.; Sender's Comments: An alternative explanation is that based on the mechanism of action of mRNA-1273 causal association between the event of COVID-19 and mRNA-1273 is assessed as not applicable.
patient reported feeling light headedness, denied SOB, difficulty breathing or continuity of symptom pt did appear flushed. she was advised  to lay flat and hydrated.  patient reported feeling better after a few minute after instructed. she may leave after full 15 minutes of observation if symptom did not persist. Patient left in good health after 15 minutes
Extreme pain and inflammation in both arms.  Ongoing inability to type, hold my phone or work.  May have triggered autoimmune disorder per doctor.
LD site of Dtap shot described as red, hot, hard, swollen to size of a baseball. First seen this AM on waking. Mother denies fever, vomiting, poor appetite, dizziness.
Pt required COVID testing prior to an invasive procedure, and tested positive.  She was asymptomatic for COVID
The patients grandson calls me to tell me that her grandmother developed a rash 10 days after the Moderna vaccine was administered.  HE wants to know if the vaccine could be responsible for the rash on her arm.
developed autoimmune LOTO Type one diabetes, Metformin and Insulin, sugars controlled A1C improving
Sl runny devel into a fever; status epilepticus 8-11min t103.6 had stopped when ambulance arrived began on lt side of face; middle ear infect;
Multiple nodules or rash over both left and right fingers, red, palpable, occasionally itching, present more on the index fingers. Severe itching/ rash over the left ear cartilage.
after a below freezing temperature excursion; This case was reported by a physician via call center representative and described the occurrence of incorrect storage of drug in a 2-month-old female patient who received DTPa-HBV-IPV (Pediarix) (batch number 9x3t5, expiry date 5th March 2023) for prophylaxis.   Co-suspect products included dtpa-hbv-ipv vaccine pre-filled syringe device (Pediarix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 12th July 2021, the patient received Pediarix and Pediarix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Pediarix and Pediarix Pre-Filled Syringe Device, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The physician reported that, the patient was administrated with Pediarix after a below freezing temperature excursion, which led to incorrect storage of drug. No adverse event was reported. The reporter consented to follow up. This case was 1 of 29 linked cases,reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021164791:same reporter US-GLAXOSMITHKLINE-US2021164777:same reporter US-GLAXOSMITHKLINE-US2021164775:same reporter US-GLAXOSMITHKLINE-US2021164771:same reporter US-GLAXOSMITHKLINE-US2021164769:same reporter US-GLAXOSMITHKLINE-US2021164779:same reporter US-GLAXOSMITHKLINE-US2021164783:same reporter US-GLAXOSMITHKLINE-US2021164784:same reporter US-GLAXOSMITHKLINE-US2021164786:same reporter US-GLAXOSMITHKLINE-US2021164787:same reporter US-GLAXOSMITHKLINE-US2021164788:same reporter US-GLAXOSMITHKLINE-US2021164789:same reporter US-GLAXOSMITHKLINE-US2021164791:same reporter US-GLAXOSMITHKLINE-US2021164792:same reporter US-GLAXOSMITHKLINE-US2021164793:same reporter US-GLAXOSMITHKLINE-US2021164794:same reporter US-GLAXOSMITHKLINE-US2021164795:same reporter US-GLAXOSMITHKLINE-US2021164797:same reporter US-GLAXOSMITHKLINE-US2021164798:same reporter US-GLAXOSMITHKLINE-US2021164799:same reporter US-GLAXOSMITHKLINE-US2021164800:same reporter US-GLAXOSMITHKLINE-US2021164801:same reporter US-GLAXOSMITHKLINE-US2021164802:same reporter US-GLAXOSMITHKLINE-US2021164803:same reporter US-GLAXOSMITHKLINE-US2021164804:same reporter US-GLAXOSMITHKLINE-US2021164805:same reporter US-GLAXOSMITHKLINE-US2021164806:same reporter US-GLAXOSMITHKLINE-US2021164808:same reporter US-GLAXOSMITHKLINE-US2021164800:
Moderna COVID-19 vaccine was administered to the patient with more than 12 hours after the vial was first punctured; The vial was first punctured on 04-Apr-2022 and administered on 05-Apr-2022. The vial was stored in refrigerator post puncture; This spontaneous case was reported by a nurse and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Moderna COVID-19 vaccine was administered to the patient with more than 12 hours after the vial was first punctured) and PRODUCT STORAGE ERROR (The vial was first punctured on 04-Apr-2022 and administered on 05-Apr-2022. The vial was stored in refrigerator post puncture) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045L21A) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: JANSSEN COVID-19 VACCINE (Primary series J and J Vaccine). Past adverse reactions to the above products included No adverse event with JANSSEN COVID-19 VACCINE.    On 05-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Apr-2022, the patient experienced PRODUCT STORAGE ERROR (The vial was first punctured on 04-Apr-2022 and administered on 05-Apr-2022. The vial was stored in refrigerator post puncture). On 05-Apr-2022, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Moderna COVID-19 vaccine was administered to the patient with more than 12 hours after the vial was first punctured). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Moderna COVID-19 vaccine was administered to the patient with more than 12 hours after the vial was first punctured) and PRODUCT STORAGE ERROR (The vial was first punctured on 04-Apr-2022 and administered on 05-Apr-2022. The vial was stored in refrigerator post puncture) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The patient took the 1st booster vaccine.  It was reported that first booster dose of Moderna COVID-19 vaccine was administered to the patient with more than 12 hours after the vial was first punctured. The vial was initially stored in the refrigerator on 04-Apr-2022. The vial was first punctured on 04-Apr-2022 at 1:55 PM and vaccine was administered on 05-Apr-2022 at 9:00 AM - 1:40 PM EST. The vial was stored in refrigerator post puncture.   Total amount of time the vial was exposed to room temperature range was reported as unknown, the vial was not exposed to room temperature for >24 hours.  The vial did not undergo any temperature excursions.
This is a spontaneous report from a contactable consumer. An adult female patient (unknown if pregnant), of unspecified age, received BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), via an unspecified route of administration, on an unknown date, single dose, for COVID-19 immunisation. The patient's medical history: unknown. Prior to vaccination, it was unknown whether patient was diagnosed with COVID-19. Since the vaccination, it was unknown whether patient tested for COVID-19. It was unknown whether patient received any other vaccines within four weeks prior to the vaccination. Concomitant medication within 2 weeks of vaccination: unknown. On an unknown date after the vaccination, patient did not feel well. The clinical course as follows: On Apr 9, 2021, the reporter was at a small gathering and met a prior coworker (the patient). Later, patient took the Pfizer COVID-19 vaccine. The reporter called on Apr 9, 2021 to report the event but couldn't reach a live person to document the event. The reporter called again on Apr 10, 2021 and received instruction to report via the website. It was unknown whether any therapeutic measures were taken as a result of the event. The clinical outcome of the event (did not feel well) was unknown at the time of the report. No follow-up attempts possible. Information about batch number cannot be obtained. Amendment: This follow-up report is being submitted to amend previously reported information: Added information that it was unknown if patient was pregnant, and vaccine facility information updated.
Patient indicated that with second dose of the Pfizer vaccine that he felt lightheaded afterwards, while waiting 15 minutes post vaccine.  But after the full 15 minutes he was fine.  Knowing that I encouraged the patient to remain seated in the vaccination room post vaccine until he felt able and comfortable to leave.  Shortly after giving the vaccine he described that he felt lightheaded and warm.  Gave him some water to drink, which he sipped on.  He proceeded to feel lightheaded, was turning pale, sweating and then passed out., head dropped and he did not respond to his name being called or tapping him on the shoulder.  911 was called and he became conscious within minutes, EMT arrived.  They took him to the hospital due to low blood pressure and heartrate.
LOCALIZED SWELLING. PATIENT TOOK 2 IBUPROFEN THAT SHE HAD. WE PROVIDED WATER. PATIENT SAT IN IMMUNIZATION ROOM FOR 10 MINUTES. SWELLING BEGAN TO REDUCE. PATIENT SAT IN LOBBY FOR AN ADDITIONAL 10 MINUTES. I PROVIDED HER WITH A 25MG BENADTYL TO TAKE ONCE SHE GOT HOME. PATIENT WAS CONTACTED BY PHONE AT 4:30PM AND SHE STATED THAT SHE IS OKAY. SWELLING OCCURRED WITH THE FLUCELVAX VACCINATIONATION INSTANTLY
26 hours after my second Moderna Vaccine I experienced these severe/painful symptoms: * Head felt like it was going to explode, especially forehead and back of head. Back of head felt like I was whacked with something. This did not feel like a headache, it was much worse than any head pain I have ever experienced. * My eyeballs felt like they were on fire. * Neck lymph nodes very swollen and painful. Pain radiated to my ears and jaw. Pain was so severe, I was thinking of going to emergency room. After 6 hours of excruciating pain, I took 1- 500 mg Tylenol at 9:00 pm. Pain did decrease to a bearable level in 1 hour.
hand pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (hand pain) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (hand pain). At the time of the report, PAIN IN EXTREMITY (hand pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter. No treatment information was provided.